Prevalence of Darunavir Resistance in the United States from 2010 to 2017

AIDS Research and Human Retroviruses
Kimberley BrownErkki Lathouwers

Abstract

The emergence and transmission of antiretroviral drug resistance have been and remain a concern among people living with human immunodeficiency virus (HIV)-1 infection. The protease inhibitor (PI) darunavir has been approved for use in the United States for more than 10 years and has demonstrated a high barrier to resistance. Previous analyses identified significant reductions in the prevalence of samples with darunavir resistance-associated mutations (RAMs) and with phenotypic resistance to darunavir and other PIs between 2006 and 2012. This analysis extends those findings by evaluating darunavir and PI resistance among clinical samples submitted for routine drug resistance testing (combined genotyping and phenotyping) in the United States from 2010 to 2017. Frequencies of 11 darunavir and 23 primary PI RAMs, and phenotypic susceptibility, were assessed yearly among all samples and in a subset of samples with distinct phenotypic resistance to one or more PIs. Among all samples (N = 60,760), the proportion with 0 darunavir RAMs was 91.7% in 2010 and 95.8% in 2017. The proportions of all samples with phenotypic susceptibility to darunavir, atazanavir, and lopinavir were, respectively, 97.4%, 94.2%, and 94.7% in 2010 and 98.6%, 9...Continue Reading

References

Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Mar 11, 2008·AIDS Research and Human Retroviruses·Sandra de MeyerMarie-Pierre de Béthune
Mar 17, 2011·Infectious Disorders Drug Targets·Jean B NachegaRobert Gross
Sep 12, 2013·Current Opinion in Virology·Janet D Siliciano, Robert F Siliciano
Dec 12, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David B HannaRobert C Kaplan
May 17, 2018·Expert Opinion on Pharmacotherapy·Eugènia Negredo, Bonaventura Clotet

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.